R&D and UK operational update

Paris, France and Camberley, UK – 23 April 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on the progress of its near-term COVID-19 research and development (R&D) programmes to address rapidly evolving testing demands, particularly as SARS-CoV-2 continues to mutate around the world. Novacyt also provides

Visit Page

Note d’informations sur la publication des résultats de l’exercice 2020

Paris, France et Camberley, Royaume-Uni – 22 Avril 2021 – Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT), spécialiste international du diagnostic clinique, informe qu’à la suite de l’annonce faite le 9 avril 2021, les résultats financiers audités de la Société pour l’exercice clos le 31 décembre 2020 seront désormais publiés le 29 juin 2021. http://novacyt.com/wp-content/uploads/2021/04/Novacyt-Notice-of-Results-22.04.2021-FRENCH.pdf

Visit Page

Update on Notice of 2020 Full Year Results

Paris, France and Camberley, UK – 22 April 2021 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that following the announcement on 9 April 2021, the Company now intends to report its audited financial results for the year ended 31 December 2020 on 29 June 2021. http://novacyt.com/wp-content/uploads/2021/04/Novacyt-Notice-of-Results-22.04.21-ENGLISH.pdf

Visit Page